Publication | Open Access

Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLR

UrologySecond-line Pembrolizumab TreatmentGenitourinary CancerMedicineImmunologyPre-chemo NlrUrothelial Cancer RegardlessImmune Checkpoint InhibitorCancer TreatmentOncology